Pipeline
Pipeline Overview
CNTY-101 is an iPSC-derived CD19 targeting allogeneic iNK cell therapy with 6 precision gene edits powered by Century’s Allo-Evasion™ technology, which enables repeat dosing without the need for continued lymphodepletion (LD). CNTY-101’s Allo-Evasion™ edits are designed to overcome the three major pathways of host versus graft rejection: CD8+ T cells, CD4+ T cells and NK cells. CNTY-101 is also engineered to secrete IL15 which provides a pro-survival signal to compete with the host immune repertoire when infused in the absence of LD, as well as a safety switch (EGFR sequence) that enables the elimination of the cells by Cetuximab® if needed.
CNTY-101 is currently being evaluated in the Phase 1 CALiPSO-1 trial (NCT06255028) for moderate to severe systemic lupus erythematosus and lupus nephritis.
CNTY-108 is an iPSC-derived CD19 targeting allogeneic iNK or γδ iT product candidate for autoimmune diseases. It is engineered with an augmented suite of Century’s Allo-Evasion™ technology, expanding the scope of protection against host immune effector mechanisms, which enables repeat dosing without the need for continued lymphodepletion (LD). CNTY-108’s Allo-Evasion™ edits are designed to overcome the three major pathways of host versus graft rejection: CD8+ T cells, CD4+ T cells and NK cells. CNTY-108 is also engineered to express a chimeric IL15/IL15 receptor which provides a pro-survival signal to compete with the host immune repertoire when infused in the absence of LD.
CLDE-308 is a CD19 targeting CD4+ and CD8+ αβ iT product candidate for autoimmune diseases. It is engineered with an augmented suite of Century’s Allo-Evasion™ technology, expanding the scope of protection against host immune effector mechanisms, which enables repeat dosing without the need for continued lymphodepletion (LD). CLDE-308’s Allo-Evasion™ edits are designed to overcome host versus graft rejection mediated by CD8+ T cells, CD4+ T cells, NK cells and anti-drug antibodies. CLDE-308 is being developed based on a proprietary process that is capable of controlling iPSC differentiation toward definitive hematopoiesis and the generation of adaptive T cells.
CLDE-361 is a BCMA targeting CD4+ and CD8+ αβ iT product candidate for myasthenia gravis. It is engineered with an augmented suite of Century’s Allo-Evasion™ technology, expanding the scope of protection against host immune effector mechanisms, which enables repeat dosing without the need for continued lymphodepletion (LD). CLDE-361’s Allo-Evasion™ edits are designed to overcome host versus graft rejection mediated by CD8+ T cells, CD4+ T cells, NK cells and anti-drug antibodies. CLDE-361 is being developed based on a proprietary process that is capable of controlling iPSC differentiation toward definitive hematopoiesis and the generation of adaptive T cells.
CNTY-101 is an iPSC-derived CD19 targeting allogeneic iNK cell therapy with 6 precision gene edits powered by Century’s Allo-Evasion™ technology, which enables repeat dosing without the need for continued lymphodepletion (LD). CNTY-101’s Allo-Evasion™ edits are designed to overcome the three major pathways of host versus graft rejection: CD8+ T cells, CD4+ T cells and NK cells. CNTY-101 is also engineered to secrete IL15 which provides a pro-survival signal to compete with the host immune repertoire when infused in the absence of LD, as well as a safety switch (EGFR sequence) that enables the elimination of the cells by Cetuximab® if needed.
CNTY-101 is currently being evaluated in the Phase 1 ELiPSE-1 trial (NCT05336409) for relapsed or refractory CD19 positive B-cell lymphomas.
CNTY-102 is an iPSC-derived dual CD19/CD22 targeting γδ iT product candidate for relapsed/refractory lymphoma and other B-cell malignancies. Dual targeting of CNTY-102 is designed to counter antigen escape relapse, which is a major limiting factor for durability of CD19 CAR-T therapies. It is engineered with an augmented suite of Century’s Allo-Evasion™ technology, expanding the scope of protection against host immune effector mechanisms, which enables repeat dosing without the need for continued lymphodepletion (LD). CNTY-102’s Allo-Evasion™ edits are designed to overcome the three major pathways of host versus graft rejection: CD8+ T cells, CD4+ T cells and NK cells. CNTY-102 is also engineered to express a chimeric IL15/IL15 receptor which provides a pro-survival signal to compete with the host immune repertoire when infused in the absence of LD.
CLDE-308 is a CD19 targeting CD4+ and CD8+ αβ iT product candidate for B-cell malignancies. It is engineered with an augmented suite of Century’s Allo-Evasion™ technology, expanding the scope of protection against host immune effector mechanisms, which enables repeat dosing without the need for continued lymphodepletion (LD). CLDE-308’s Allo-Evasion™ edits are designed to overcome host versus graft rejection mediated by CD8+ T cells, CD4+ T cells, NK cells and anti-drug antibodies. CLDE-308 is being developed based on a proprietary process that is capable of controlling iPSC differentiation toward definitive hematopoiesis and the generation of adaptive T cells.
CNTY-104 is an iPSC-derived CAR-iNK or CAR-iT multi-specific product candidate for acute myeloid leukemia currently being developed in collaboration with Bristol Myers Squibb.
CNTY-106 is an iPSC-derived CAR-iNK or CAR-iT multi-specific product candidate for multiple myeloma currently being developed in collaboration with Bristol Myers Squibb.
CNTY-107 is an iPSC-derived Nectin-4 targeting CAR γδ iT product candidate for solid tumors. CNTY-107 is engineered with Allo-Evasion™ edits and other features to provide cytokine support, enhance tumor cell killing and cell fitness.
An undisclosed iT cell therapy focused research program for solid tumors.
An undisclosed iNK or iT cell therapy focused research program for hematologic and solid tumors.
Autoimmune Diseases
Hematologic Tumors
Solid Tumors